In the shadow of a pandemic that confounded prediction, researchers at Massachusetts General Hospital found an unlikely ally in an old and familiar tool: a routine blood test, long used to detect anaemia and heart disease, that quietly revealed which COVID-19 patients were most likely to die. The red cell distribution width, or RDW, proved nearly three times more predictive of mortality than chance alone — and held its power even when age and underlying conditions were accounted for. Science, in this moment, did not arrive with something new, but with a deeper reading of something already in h
Blood test could predict Covid-19 mortality risk, study finds
Related Coverage
A teenager from Caernarfon experienced sudden onset menopause following an ovarian cancer diagnosis, highlighting unexpe…
JNS.org · Aug 19 Israeli study: Focused attention may reduce inflammatory responseBar-Ilan University researchers found that deliberately focusing attention on inflamed skin areas reduced inflammatory r…
foodsafetynews.com · Aug 19 UK Salmonella outbreak sickens 207, linked to imported eggsA Salmonella outbreak across the UK has infected 207 people with one death, traced to contaminated imported eggs served …
eNCA · Aug 19 DRC Ebola outbreak spreading faster than any previous epidemic, WHO warnsWHO warns the DRC Ebola outbreak is moving faster than any previous epidemic, with over 2,300 deaths from nearly 5,000 c…
Geopolitical Impact
Medical research on COVID-19 mortality prediction has minimal geopolitical implications; primarily a public health advancement with potential global healthcare benefits.
No significant power shifts. This is a scientific discovery that could benefit all nations equally if adopted universally in healthcare systems.
Bias & Framing
Article presents medical research findings on RDW blood test correlation with COVID-19 mortality in straightforward, factual manner with minimal apparent bias.
Science-based reporting using expert authority and empirical data. Frames discovery as potentially beneficial for patient care through early risk identification and targeted interventions.
Economic Lens
Blood test discovery (RDW) could enable early identification of high-risk COVID-19 patients, potentially reducing mortality through targeted interventions and improving healthcare resource allocation.
Patients benefit from earlier risk stratification enabling timely aggressive treatment, potentially reducing mortality rates and improving outcomes. May reduce unnecessary hospitalizations for low-risk patients and lower out-of-pocket costs through more efficient care pathways.
Regulatory bodies (FDA, EMA) may expedite approval of RDW-based diagnostic protocols. Healthcare systems could adopt RDW screening as standard COVID-19 admission procedure. Insurance reimbursement policies may evolve to incentivize early risk assessment. Public health agencies may integrate this into pandemic preparedness frameworks.